Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

DC Investment Partners

HBM Healthcare Investments AG

Adage Capital Management

RA Capital Management

Longwood Fund

MPM Capital

Soleus Capital

Sphera Global Healthcare Fund

Taiho Ventures

UPMC Enterprises

Werewolf Therapeutics

We are excited to share preliminary monotherapy data from our WTX-124 Phase 1/1b clinical trial at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. https://bit.ly/45SOV8Y #ImmunoOncology #Cytokines #SITC2023 #HOWL

Excited to be at SITC in San Diego to present 6 posters sharing Wereowlf’s exciting advancement and data!

We’re #hiring a new Accountant in Watertown, Massachusetts. Apply today or share this post with your network.

Werewolf will be @ SITC and would welcome discussions with investors and partners. Reach out to me! See you in San Diego.

We are looking forward to the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Be sure to visit our six poster presentations, including interim first-in-human clinical data from our WTX-124 Phase 1/1b study. Learn More: https://lnkd.in/gjjR58w3
#ImmunoOncology #Cytokines #SITC2023 $HOWL

On Sunday 9/24 we are honored to recognize #WorldCancerResearchDay and raise awareness for #cancerresearch. At Werewolf we remain committed to transforming cancer treatment through innovation. Learn more here https://werewolftx.com/

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	633K -	1.02M 61.30%	2.04M 99.51%	1.22M 40.06%	1.34M 9.42%
accumulated other comprehensive income loss			-179.25M -
cash and cash equivalents	17.90M -	92.57M 417.27%	157.53M 70.18%	129.31M 17.91%	134.34M 3.89%
cash and short term investments	17.90M -	92.57M 417.27%	157.53M 70.18%	129.31M 17.91%	134.34M 3.89%
common stock	2K -	2K 0%	2K 0%	3K 50%	4K 33.33%
deferred revenue				6.53M -	907K 86.11%
deferred revenue non current				1.13M -	433K 61.61%
deferrred tax liabilities non current					10.56M -
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	2.54M -	1.86M 26.67%	14.59M 682.67%	12.60M 13.63%	32.66M 159.17%
long term investments					21.02M -
net debt	-14.76M -	-90.03M 509.99%	-141.87M 57.58%	-114.63M 19.20%	-82.42M 28.10%
net receivables				6.93M -	1.35M 80.51%
other assets					1 -
other current assets	167K -	344K 105.99%	3.54M 928.20%	3.96M 11.87%	2.68M 32.35%
other current liabilities	816K -	3.59M 339.46%	8.77M 144.42%	14.15M 61.46%	8.86M 37.39%
other liabilities
other non current assets	208K -	362K 74.04%	1.86M 412.98%	2.59M 39.69%	594.00K 77.10%
other non current liabilities	41.40M -	141.11M 240.88%		191K -	433K 126.70%
othertotal stockholders equity	102K -		405.68M -	429.04M 5.76%	455.44M 6.15%
preferred stock			179.25M -
property plant equipment net	3.41M -	3.12M 8.39%	16.32M 422.90%	17.45M 6.90%	14.85M 14.93%
retained earnings	-24.41M -	-51.87M 112.49%	-252.90M 387.60%	-306.70M 21.28%	-344.07M 12.18%
short term debt	595K -	677K 13.78%	1.07M 58.35%	2.08M 94.40%	8.28M 297.07%
short term investments
tax assets
tax payables
total assets	21.68M -	96.40M 344.66%	179.25M 85.95%	160.25M 10.60%	174.83M 9.10%
total current assets	18.06M -	92.91M 414.39%	161.07M 73.35%	140.20M 12.96%	138.37M 1.31%
total current liabilities	2.04M -	5.28M 158.51%	11.87M 124.72%	23.99M 102.03%	19.38M 19.22%
total debt	3.14M -	2.54M 19.00%	15.66M 516.33%	14.68M 6.24%	51.92M 253.60%
total investments					21.02M -
total liabilities	45.98M -	148.26M 222.43%	26.46M 82.15%	37.91M 43.25%	63.46M 67.40%
total liabilities and stockholders equity	21.68M -	96.40M 344.66%	179.25M 85.95%	160.25M 10.60%	174.83M 9.10%
total non current assets	3.62M -	3.48M 3.65%	18.18M 421.87%	20.05M 10.25%	36.46M 81.91%
total non current liabilities	43.94M -	142.98M 225.40%	14.59M 89.80%	13.92M 4.59%	44.08M 216.70%
total stockholders equity	-24.30M -	-51.86M 113.39%	152.79M 394.60%	122.34M 19.93%	111.37M 8.96%

NASDAQ:HOWL

Werewolf Therapeutics, Inc.

Last Close

2.03

25/09 14:38

Market Cap

95.60M

Beta: 0.21

Volume Today

47.32K

Avg: 55.98K

PE Ratio

−6.10

PFCF: −5.35

Preview